Simpler treatment for lung flare-ups in kids with CF
Part of Digestive system, Genetic & congenital, Lungs & breathing clinical trials.
This study tests a streamlined approach to managing sudden lung symptoms (pulmonary exacerbations) in children with cystic fibrosis. It aims to see if a simpler treatment plan works as well as standard care, which could mean less time in the hospital and fewer disruptions to daily life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Child must be between 3 and 18 years old (exact age group depends on the study cohort).
- Child must have a confirmed diagnosis of cystic fibrosis (CF).
- For most children: they must be on a highly effective CF modulator drug (like Trikafta) for at least 3 months before joining.
- Child must be able to do a lung function test (blowing into a tube) and have at least 50% of normal lung function.
- Family must be able to receive text messages and use the internet.
- Child cannot have had antibiotics (by mouth or IV) or steroids in the 2 weeks before joining, and no more than 2 IV-treated lung flare-ups in the past year.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well a highly effective cystic fibrosis (CF) medicine works in infants and young children, and what biological changes it causes. It may help families understand whether the medicine improves CF function and related measures early in life.
This study standardizes how IV aminoglycoside antibiotics are given during a 14-day treatment for cystic fibrosis (CF) lung flare-ups. It may help make treatment more consistent and easier to manage for people who need IV antibiotics.
This study looks at sinus problems in young children with cystic fibrosis. One group of children starts a new medicine called a highly effective modulator (like Trikafta), and the other group does not take this medicine. The goal is to see how the medicine affects sinus health over time.
This trial tests how well cystic fibrosis (CF) medicine works for you using an “n-of-1” approach, meaning you try treatments in a structured, repeated way to see what helps you most. It may help your care team choose the best option for your specific CF genetics and health status.
This trial tests an online program designed to help people with cystic fibrosis avoid exacerbations (sudden worsening of symptoms). You participate from home using a device with internet, camera, and microphone.
This trial tests a new inhaled medicine (BMD003) that delivers CFTR mRNA to help correct the genetic defect causing cystic fibrosis. It is for patients who are 12 years or older, have stable CF, and meet certain lung function and weight criteria.
Hear when a new Cystic Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.